SureClinical Launches Eclinical Ecosystem ECO Bundle
SureClinical announced the launch of their new Eclinical Ecosystem ECO Applications and Platform Bundle. The ECO Bundle connects people, programs, projects, and processes everywhere for a singular view of clinical data. The ECO Bundle centralizes clinical intelligence and reporting across multiple applications, data points and systems, allowing distributed clinical research teams to collaborate within a single, modern application experience.
The ECO bundle supports project management, document management, site management and quality management. With over 500 global clinical trials and multiple audits, and centralized documents and data in one repository, current SureClinical clients have the freedom to select and connect applications from multiple vendors, apps, and projects for quantifiable time-efficient delivery of new treatments and therapies.
The ECO bundle includes SureClinical’s SureCTMS, electronic Trial Master File (ETMF), Investigator Site File (ISF), Quality Management Software (QMS) and Clinical Trial Management (CTMS) applications. SureISF is a cloud-based regulatory document management solution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
